About

Creatv's revolutionary liquid biopsy and innovative platform provides a highly personalized test called LifeTracDxTM with broad clinical applications for cancer. LifeTracDxTM can • detect solid tumors as early as stage I before symptoms develop, • provide companion diagnostics without tissue biopsy, • predict treatment response within 30-60 days for most therapies including immunotherapy, • provide copious unfragmented tumor DNA for sequencing, and • detect recurrence earlier than imaging. Clinical application of these highly sensitive and specific tests will reduce morbidity and significantly improve patient outcomes.